Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/02/2023* -- Results Q4 2022 -- -0.39 --
08/15/2022 -- Results Q2 2022 -0.17 -0.40 57.50%
05/16/2022 -- Results Q1 2022 -0.49 -0.28 -75.91%
03/02/2022 -- Results Q4 2021 -0.31 -0.01 -3.00K%
11/19/2021 -- Results Q3 2021 -0.23 -0.28 17.86%
08/10/2021 -- Results Q2 2021 -0.23 -0.36 35.66%
05/17/2021 -- Results Q1 2021 -0.11 -0.41 73.17%
03/01/2021 -- Results Q4 2020 -0.50 -0.41 -22.70%
*Estimated Date/Time

Earnings

Next Report Date 03/02/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/15/2022
Beat/Miss Upgrade
Return Since -11.18%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
URL https://www.acertx.com
Investor Relations URL http://www.opexatherapeutics.com/investors-relations/why-invest/default.aspx
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 02, 2023 (est.)
Last Earnings Release Aug. 15, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-51.92%
-66.78%
45.37%
45.27%
-80.07%
-34.66%
-12.98%
-40.79%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.17%
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-56.52%
-44.57%
-56.37%
48.58%
-52.96%
5.47%
10.67%
-77.09%
32.26%
-61.17%
-88.94%
-77.05%
-79.57%
12.53%
-8.16%
83.59%
-58.94%
14.36%
-9.25%
-20.87%
-26.99%
71.01%
-21.87%
1.26%
-18.01%
As of December 01, 2022.

Profile

Edit
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
URL https://www.acertx.com
Investor Relations URL http://www.opexatherapeutics.com/investors-relations/why-invest/default.aspx
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 02, 2023 (est.)
Last Earnings Release Aug. 15, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ACER Tweets